Vera Therapeutics (VERA) Competitors $22.57 -0.04 (-0.18%) Closing price 04:00 PM EasternExtended Trading$22.55 -0.02 (-0.09%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA vs. NUVL, AXSM, CRSP, ABVX, MRUS, CYTK, VKTX, TGTX, KRYS, and ACADShould you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Nuvalent (NUVL), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Abivax (ABVX), Merus (MRUS), Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Vera Therapeutics vs. Its Competitors Nuvalent Axsome Therapeutics CRISPR Therapeutics Abivax Merus Cytokinetics Viking Therapeutics TG Therapeutics Krystal Biotech ACADIA Pharmaceuticals Nuvalent (NASDAQ:NUVL) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings. Which has more risk and volatility, NUVL or VERA? Nuvalent has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Do analysts prefer NUVL or VERA? Nuvalent currently has a consensus target price of $118.91, suggesting a potential upside of 56.29%. Vera Therapeutics has a consensus target price of $63.00, suggesting a potential upside of 179.13%. Given Vera Therapeutics' higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Vera Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Does the media refer more to NUVL or VERA? In the previous week, Nuvalent had 8 more articles in the media than Vera Therapeutics. MarketBeat recorded 11 mentions for Nuvalent and 3 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.22 beat Nuvalent's score of 0.99 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, NUVL or VERA? Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.90-15.53Vera TherapeuticsN/AN/A-$152.15M-$3.58-6.30 Do insiders & institutionals have more ownership in NUVL or VERA? 97.3% of Nuvalent shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 10.2% of Nuvalent shares are held by insiders. Comparatively, 16.3% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is NUVL or VERA more profitable? Nuvalent's return on equity of -32.58% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -32.58% -30.14% Vera Therapeutics N/A -46.70%-39.46% SummaryVera Therapeutics beats Nuvalent on 7 of the 13 factors compared between the two stocks. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERA vs. The Competition Export to ExcelMetricVera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.44B$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-6.3021.1431.1525.97Price / SalesN/A399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book3.078.079.116.39Net Income-$152.15M-$54.72M$3.26B$265.66M7 Day Performance4.78%2.62%2.11%1.98%1 Month Performance1.26%7.63%5.12%1.33%1 Year Performance-42.31%13.11%31.25%21.15% Vera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERAVera Therapeutics3.7647 of 5 stars$22.57-0.2%$63.00+179.1%-43.4%$1.44BN/A-6.3040Positive NewsNUVLNuvalent3.284 of 5 stars$75.01-1.4%$119.60+59.4%-10.9%$5.48BN/A0.0040News CoverageAnalyst ForecastInsider TradeAXSMAxsome Therapeutics4.8083 of 5 stars$111.13+1.8%$178.00+60.2%+33.2%$5.45B$385.69M0.00380News CoveragePositive NewsCRSPCRISPR Therapeutics3.8292 of 5 stars$57.59-3.6%$71.60+24.3%+5.7%$5.43B$37.31M0.00460ABVXAbivax2.8837 of 5 stars$70.01-0.6%$92.33+31.9%+544.4%$5.32BN/A0.0061Short Interest ↑MRUSMerus2.3391 of 5 stars$66.00-1.9%$88.50+34.1%+24.4%$5.09B$36.13M0.0037News CoveragePositive NewsCYTKCytokinetics3.7434 of 5 stars$38.95+0.7%$71.58+83.8%-32.8%$4.63B$18.47M-7.64250News CoverageVKTXViking Therapeutics4.0243 of 5 stars$42.09+5.1%$86.92+106.5%-60.4%$4.50BN/A-27.5120Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3543 of 5 stars$27.73-1.2%$46.25+66.8%+14.8%$4.46B$329M74.95290Positive NewsKRYSKrystal Biotech4.7511 of 5 stars$146.30-2.6%$210.75+44.1%-27.7%$4.35B$290.52M30.54210News CoverageAnalyst ForecastACADACADIA Pharmaceuticals3.9708 of 5 stars$25.06-1.1%$28.88+15.2%+55.6%$4.27B$957.80M18.84510Insider Trade Related Companies and Tools Related Companies Nuvalent Competitors Axsome Therapeutics Competitors CRISPR Therapeutics Competitors Abivax Competitors Merus Competitors Cytokinetics Competitors Viking Therapeutics Competitors TG Therapeutics Competitors Krystal Biotech Competitors ACADIA Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access